Peter Lapsley
Peter Lapsley
Competing interests
1) Have you in the past five years accepted the following from an organisation that may in any way gain or lose financially from the publication of this paper?
a) Reimbursement for attending a symposium?
Yes in 2004, my attendance at the European Association of Dermatologists Conference was sponsored by Leo Pharmaceuticals.
b) A fee for speaking?
No
c) A fee for organising education?
No
d) Funds for research?
No
e) Funds for a member of staff?
No
f) Fees for consulting?
No
2) Have you in the past five years been employed by an organisation that may in any way gain or lose financially from the publication of this paper?
Until March 2007, I was chief executive of the Skin Care Campaign (SCC), an organisation run by patients for patients to improve dermatology services in the UK. At that time, the SCC was wholly funded (in equal measure) by 13 pharmaceutical companies - Allergan Ltd, Astellas Pharma UK, Beiersdorf Ltd, Dermal Laboratories Ltd, Galderma (UK) Ltd, Molnlycke Health Care Ltd, Reckitt Benckiser, Schering-Plough Ltd, Serono Ltd, Shire Pharmaceuticals Group plc (UK), Stiefel Laboratories (UK) Ltd and 3M Healthcare Limited.
3) Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this paper?
No
4) Have you acted as an expert witness on the subject of your study, review, editorial, or letter?
No
5) Do you have any other competing financial interests. If so, please specify.
No
Competing interest statement:
I am a patient advisor to The All-Party Parliamentary Group on Skin (APPGS) and have recently (April 2009) been appointed chairman of the APPGS Oversight Committee.
What's new
Online poll
Services
Print issues
